Can you provide the upcoming earnings date for GALMED PHARMACEUTICALS LTD?
GALMED PHARMACEUTICALS LTD (GLMD) will report earnings on 2026-03-31, after the market close.
GALMED PHARMACEUTICALS LTD (GLMD) Forecast, Price Target & Analyst Ratings
NASDAQ:GLMD • IL0011313900
Current stock price
0.49 USD
+0.02 (+3.16%)
At close:
0.48 USD
-0.01 (-2.04%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for GALMED PHARMACEUTICALS LTD (GLMD).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- Mar 31, 2026
- Period
- Q4 / 2025
- EPS Estimate
- -$0.52
- Revenue Estimate
Price Target Details & History
Consensus Price Target and Range
Mean target
N/A
Upside
N/A
From current price of $0.49 to mean target of N/A, Based on 6 analyst forecasts
Low
N/A
Median
N/A
High
N/A
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
43.33%
GLMD was analyzed by 6 analysts. The buy percentage consensus is at 43. So analysts seem to be rather negative about GLMD.
In the previous month the buy percentage consensus was at a similar level.
GLMD was analyzed by 6 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-04-04 | Maxim Group | Downgrade | Buy -> Hold |
| 2023-07-24 | Maxim Group | Upgrade | Hold -> Buy |
| 2022-08-08 | Canaccord Genuity | Downgrade | Buy -> Hold |
| 2022-08-08 | Maxim Group | Downgrade | Buy -> Hold |
| 2022-05-18 | Raymond James | Downgrade | Outperform -> Market Perform |
| 2022-05-03 | Raymond James | Maintains | Outperform |
| 2022-05-03 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2021-05-17 | Canaccord Genuity | Maintains | Buy |
| 2021-03-19 | HC Wainwright & Co. | Maintains | Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Mar 31, 2026
- Period
- Q4 / 2025
- EPS Estimate
- -$0.52
- Revenue Estimate
- Revenue Q2Q
- N/A
- EPS Q2Q
- N/A
- Number of Analysts
- 3
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
GLMD is expected to report earnings on 3/31/2026. The consensus EPS estimate for the next earnings is -0.52 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates 2025 - 2030
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 470K | 1.09M 131.91% | 2.04M 87.16% | -100.00% | 14.725M | 43.722M 196.92% | ||||||||||
| EBITDA YoY % growth | -16.71M -54.29% | -12.12M 27.47% | -10.33M 14.77% | -20.4M -116.26% | -23.766M -35.05% | N/A -8.85% | N/A 46.38% | N/A 57.64% | N/A 17.05% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -16.88M -55.15% | -12.36M 26.78% | -10.72M 13.27% | -22.068M -108.77% | -28.231M -34.99% | -34.846M -8.84% | -19.24M 46.32% | -8.361M 57.56% | -10.841M 16.29% | -7.688M -22.61% | -7.764M -1.00% | -7.882M -1.51% | -31.886M -304.57% | -19.21M 39.76% | 4.62M 124.05% | |
| Operating Margin | -3,591.49% | -1,133.94% | -525.49% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -130.46% | 10.57% | |
| EPS YoY % growth | -268.20 -56.84% | -176.40 34.23% | -102.60 41.84% | -167.31 -70.18% | -228.77 -39.18% | -242.72 2.22% | -137.70 46.97% | -32.19 68.95% | -1.32 96.64% | -2.36 -79.07% | -0.87 63.20% | -0.56 35.29% | -1.85 -229.09% | 0.74 140.33% | 4.73 535.62% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | |
|---|---|
| EPS Q2Q % growth | -0.52 |
| Revenue Q2Q % growth | |
| EBITDA Q2Q % growth | N/A |
| EBIT Q2Q % growth | -2.075M -26.20% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
16.31%
EPS Next 5 Year
20.74%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
GALMED PHARMACEUTICALS LTD / GLMD Forecast FAQ
What are the consensus estimates for GALMED PHARMACEUTICALS LTD (GLMD) next earnings?
The consensus EPS estimate for the next earnings of GALMED PHARMACEUTICALS LTD (GLMD) is -0.52 USD and the consensus revenue estimate is 0 USD.
How many analysts cover GALMED PHARMACEUTICALS LTD (GLMD) stock?
The number of analysts covering GALMED PHARMACEUTICALS LTD (GLMD) is 6.